Tuspetinib
Myelodysplastic Syndrome With Excess Blasts-2
Explore 16 assets in Myelodysplastic Syndrome With Excess Blasts-2 →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Aptose Biosciences Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03850574CT.gov Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic Syndrome With Excess Blasts-2
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuspetinib (this asset) | Aptose Biosciences Inc. | P1/2 | CCC · 48 |
| Fludarabine | Sumithira Vasu | P2 | BB |
| Gilteritinib | Stichting Hemato-Oncologie voor Volwassenen Nederland | P3 | BB |
| Cytarabine | Sumithira Vasu | P2 | BB |
| Thiotepa | Fred Hutchinson Cancer Center | P2 | B |
| Azacitidine | Aptose Biosciences Inc. | P2 | B |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P2 | B |
| Midostaurin | Stichting Hemato-Oncologie voor Volwassenen Nederland | P3 | B |
| Tacrolimus | Fred Hutchinson Cancer Center | P2 | B |
+20 more in the Myelodysplastic Syndrome With Excess Blasts-2 cohort
Other indications for Tuspetinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P1/2 | CC · 45 |
| Chronic Myelomonocytic Leukemia | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tuspetinib in Myelodysplastic Syndrome With Excess Blasts-2. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tuspetinib-myelodysplastic-syndrome-with-excess-blasts-2
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →